Pirfenidone improves adipose dysfunction and obesity-driven steatohepatitis via mTORC1 signaling

Read full text Summarise with VIRAT
Authors: Yu Seol Lee, Ji Yun Bang, Da Hyun Lee, Da Ye Kim, Shin Young Cha, Eo Jin Lee, Jisu Han, Soo Han Bae
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Obesity-driven metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are shaped by depot-specific adipose tissue dysfunction, including maladaptive expansion and visceral adipose tissue (VAT) fibrosis. Pirfenidone, an anti-fibrotic agent, improves experimental liver disease. However, its actions on adipose depots and adipose–liver crosstalk remain unclear. Here, we identify pirfenidone as a modulator of mechanistic target of rapamycin complex 1 (mTORC1)-dependent adipose tissue remodeling with divergent outputs in subcutaneous and visceral fat. In diet-induced obese MASH mice, pirfenidone decreased subcutaneous adipose tissue (SAT), inhibiting mTORC1-driven lipogenesis and enhancing oxidative lipid metabolism. Pirfenidone attenuated VAT fibrosis by suppressing an mTORC1–mothers against decapentaplegic homolog 3 (SMAD3)–yes-associated protein (YAP) axis and extracellular matrix gene programs. Pirfenidone also lowered hepatic triglycerides, improved steatosis and fibrosis, reduced hepatic mTORC1 activity. Conditioned medium from fibrotic adipocytes induced lipogenic, inflammatory, and pro-fibrotic programs in AML12, which effects that were blunted by pirfenidone. These data reveal adipose tissue-centered actions of pirfenidone that link mTORC1 remodeling to improved obesity-associated liver disease.

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Adipokines Inflammation and Metabolic Diseases Cardiovascular Disease and Adiposity

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
21 March 2026
Language
EN
Document type
Preprint